|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2009-9-2
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Novel strategies are required to provide rapid vaccine coverage in the event of an influenza pandemic. A phase I/II dose finding/formulation study was performed with a whole-virus H5N1 clade 1 A/Vietnam vaccine (2-dose priming regimen) to evaluate safety and immunogenicity. Seventy-seven of 141 subjects in this study received a booster (12-17 months after priming) with a 7.5-microg dose of a clade 2.1 A/Indonesia vaccine. The prime-boost regimen resulted in antibody responses against clade 1, 2.1, 2.2, and 2.3 viruses that were significantly higher than those after the priming regimen. These findings demonstrate that a prime-boost regimen may alleviate vaccine supply constraints in a pandemic.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0022-1899
|
|
pubmed:author |
pubmed-author:BerezukGregG,
pubmed-author:EhrlichHartmut JHJ,
pubmed-author:FritschSandorS,
pubmed-author:KistnerOtfriedO,
pubmed-author:Löw-BaselliAlexandraA,
pubmed-author:MüllerMarkusM,
pubmed-author:MaritschFriedrichF,
pubmed-author:MontomoliEmanueleE,
pubmed-author:Noel BarrettPP,
pubmed-author:OhHelen M LHM,
pubmed-author:PöllabauerEva MariaEM,
pubmed-author:PavlovaBorislava GBG,
pubmed-author:TambyahPaul APA,
pubmed-author:ZeitlingerMarkusM,
pubmed-author:van der VeldenMaikel V WMV
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
200
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1113-8
|
|
pubmed:meshHeading |
pubmed-meshheading:19712040-Animals,
pubmed-meshheading:19712040-Antibodies, Viral,
pubmed-meshheading:19712040-Cercopithecus aethiops,
pubmed-meshheading:19712040-Dose-Response Relationship, Immunologic,
pubmed-meshheading:19712040-Humans,
pubmed-meshheading:19712040-Immunization, Secondary,
pubmed-meshheading:19712040-Immunologic Memory,
pubmed-meshheading:19712040-Influenza, Human,
pubmed-meshheading:19712040-Influenza A Virus, H5N1 Subtype,
pubmed-meshheading:19712040-Influenza Vaccines,
pubmed-meshheading:19712040-Vero Cells
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.
|
|
pubmed:affiliation |
Global R&D, Baxter BioScience, Vienna, Austria.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
